Did the Demand for Crestor Shrink when Lipitor’s Patent Expired?

Cameron A, Trivedi P (2005) Microeconometrics: methods and applications. Cambridge University Press, New York

Cameron A, Trivedi P (2013) Regression analysis of count data, Second edn. New York, Cambridge University Press

Cameron A, Li T, Trivedi P, Zimmer D (2004) Modeling the differences in counted outcomes using bivariate copula models with application to Mismeasured counts. Econ J 7:566–584

DeRuiter J, Holston P (2012) Drug patent expirations and the `patent Cliff'. U.S. Pharmacist 37:12–20

Duflos G, Lichtenberg F (2012) Does competition stimulate drug utilization? The impact of changes in market structure on U.S. drug prices, marketing, and utilization. Int Rev Law Econ 32:95–109

Emerton D (2006) Patent expiries in the U.S. statin market: generics to slash market size by 80 percent over the next ten years. J Gene Med 4:73–78

Frank R (2001) Prescription drug prices: why do some pay more than others do? Health Aff 20:115–128

Frank R, Newhouse J (2008) Should drug prices be negotiated under part D of Medicare? And if so, how? Health Aff 27:33–43

Kidd J (2006) Life after statin patents expire. Nat Rev Drug Discov 5:813–814

Nichols S, Ballantyne C, Barter P, Chapman M, Erbel R, Libby P, Raichlen J, Uno K, Borgman M, Wolski K, Nissen S (2011) Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 365:2078–2087

Puig-Junoy J (2007) The impact of generic reference pricing interventions in the statin market. Health Policy 82:14–29

Sarma S, Basu K, Gupta A (2007) The influence of prescription drug insurance on psychotropic and non-psychotropic drug utilization in Canada. Soc Sci Med 65:2553–2565

Skipper N, Vejlin R (2015) Determinants of generic vs. brand drug choice: evidence from population-wide Danish data. Soc Sci Med 130:204–215